{"id":"NCT01197300","sponsor":"Novartis Pharmaceuticals","briefTitle":"1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids","officialTitle":"A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-25","primaryCompletion":"2019-02-27","completion":"2019-02-27","firstPosted":"2010-09-09","resultsPosted":"2019-09-20","lastUpdate":"2019-09-20"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Zoledronic acid","otherNames":[]}],"arms":[{"label":"Zoledronic acid","type":"EXPERIMENTAL"}],"summary":"This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids.","primaryOutcome":{"measure":"Long-term Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids.","timeFrame":"Baseline 1 (Visit 1 of the Core Study) through Month 24 (Visit 15/Final Extension Visit)","effectByArm":[{"arm":"Core Treatment Zoledronic Acid","deltaMin":7,"sd":null},{"arm":"Core Treatment: Placebo","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Australia","Canada","Hungary","Russia","South Africa","United Kingdom"]},"refs":{"pmids":["17476007","9753709","10562298","11870242","17943849"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":10},"commonTop":["Pyrexia","Arthralgia","Headache","Abdominal pain","Nausea"]}}